NDC 0006-4963
ZOSTAVAX
Zoster Vaccine Live
ZOSTAVAX is a Subcutaneous Injection, Powder, Lyophilized, For Suspension in the Vaccine category. It is labeled and distributed by Merck Sharp & Dohme Llc. The primary component is Varicella-zoster Virus Strain Oka/merck Live Antigen.
| Product ID | 0006-4963_4608a61b-13c5-44f0-b3fd-eab84bf16b92 |
| NDC | 0006-4963 |
| Product Type | Vaccine |
| Proprietary Name | ZOSTAVAX |
| Generic Name | Zoster Vaccine Live |
| Dosage Form | Injection, Powder, Lyophilized, For Suspension |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2006-05-25 |
| Marketing Category | BLA / BLA |
| Application Number | BLA125123 |
| Labeler Name | Merck Sharp & Dohme LLC |
| Substance Name | VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN |
| Active Ingredient Strength | 19400 [PFU]/.65mL |
| Pharm Classes | Actively Acquired Immunity [PE], Chickenpox Vaccine [CS], Herpes Zoster Vaccine [CS], Live Attenuated Herpes Zoster Virus Vaccine [EPC], Live Attenuated Varicella Zoster Virus Vaccine [EPC], Vaccines, Attenuated [CS] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 0006-4963-00
1 VIAL, SINGLE-DOSE in 1 CARTON (0006-4963-00) > .65 mL in 1 VIAL, SINGLE-DOSE (0006-4963-01)
| Marketing Start Date | 2006-05-25 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 0006-4963-41 [00006496341]
ZOSTAVAX INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
| Marketing Category | BLA |
| Application Number | BLA125123 |
| Product Type | VACCINE |
| Billing Unit | EA |
| Marketing Start Date | 2006-05-25 |
NDC 0006-4963-00 [00006496300]
ZOSTAVAX INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
| Marketing Category | BLA |
| Application Number | BLA125123 |
| Product Type | VACCINE |
| Billing Unit | EA |
| Marketing Start Date | 2006-05-25 |
NDC 0006-4963-01 [00006496301]
ZOSTAVAX INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
| Marketing Category | BLA |
| Application Number | BLA125123 |
| Product Type | VACCINE |
| Billing Unit | EA |
| Marketing Start Date | 2006-05-25 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN | 19400 [PFU]/.65mL |
Pharmacological Class
- Live Attenuated Varicella Zoster Virus Vaccine [EPC]
- Actively Acquired Immunity [PE]
- Vaccines
- Attenuated [CS]
- Chickenpox Vaccine [CS]
- Live Attenuated Herpes Zoster Virus Vaccine [EPC]
- Herpes Zoster Vaccine [CS]
Trademark Results [ZOSTAVAX]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ZOSTAVAX 85148115 4422246 Live/Registered |
MERCK SHARP & DOHME CORP. 2010-10-08 |
 ZOSTAVAX 78877599 not registered Dead/Abandoned |
Merck Sharp & Dohme Corp. 2006-05-05 |
 ZOSTAVAX 76483458 3042193 Live/Registered |
MERCK SHARP & DOHME CORP. 2003-01-21 |
 ZOSTAVAX 75751442 not registered Dead/Abandoned |
Merck & Co., Inc. 1999-07-14 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.